CardioVisual

Chronic stress = cardiovascular risk.

Sustained sympathetic activation drives hypertension, endothelial dysfunction, pro-inflammatory states, and arrhythmogenesis, and is associated with increased incidence of MI, arrhythmia, and Takotsubo cardiomyopathy.

In men, the clinical picture is shaped by higher sympathetic reactivity, lower rates of help-seeking, and frequent clustering with other modifiable risk factors. The result is a stress burden that often goes unaddressed until cardiovascular disease becomes clinically apparent.

Dr. Sahib Khalsa's talk on the sympathetic nervous system and stress is now available on https://hcp.medicalvisual.com/video-details/the-sympathetic-nervous-system-and-stress-bhns-, covering the underlying physiology, clinical implications, and emerging directions in autonomic-targeted care. Watch now!

Sleep apnea does more than disrupt sleep. The repetitive cycle of hypoxemia and arousal drives autonomic instability with direct ECG consequences.

During apneic episodes, vagal tone rises, producing bradycardia and sinus pauses. Post-arousal sympathetic surges can trigger sinus tachycardia, SVT, and in susceptible patients, nonsustained VTach. The AFib connection is the most clinically significant: OSA increases incidence, complicates rate control, and reduces long-term success after cardioversion when left untreated.

Men are 2 to 3 times more likely to have obstructive sleep apnea than women. During Men's Health Awareness Month, that disproportionate risk and its arrhythmia burden deserve more clinical attention.

Learn more about heart rhythm and rate and master ECG interpretation with the full ECG course taught by Matt Holden from Scope Education, available on hcp.medicalvisual.com!

EP Live Austin 2026 is over, but the learning still continues!

If you missed the two days of live EP cases from St. David's Medical Center in Austin, get ready to watch at your own pace.

Sessions cover the latest ablation technology including emerging investigational platforms, trial results presented directly by the investigators, expert perspectives on EP, and live cases from the lab with real-time clinical decision-making.

Access the full EP Live conference videos only at hcp.medicalvisual.com. Coming soon!

Cardiovascular disease remains the leading cause of death in men, and the patterns behind that statistic are clinically distinct. Men develop coronary disease earlier, face a greater lifetime risk of atrial fibrillation, and account for the majority of sudden cardiac deaths.

Risk is not uniform. South Asian men face disproportionate CAD risk that standard calculators frequently underestimate. Black men carry substantially higher rates of sudden cardiac death and hypertension-driven cardiac disease. Screening thresholds based on average-population data will miss high-risk individuals in these groups.

Learn more about cardiovascular diseases, prevention, and therapies only on hcp.medicalvisual.com!

Current SCD risk stratification relies heavily on LVEF below 35% as the primary threshold for ICD candidacy. The problem is well documented: a significant proportion of patients who die suddenly do not meet that threshold, and many who receive ICDs never use them. The selection tool is blunt.

AI addresses this by integrating ECG features, echocardiographic strain, cardiac MRI scar characterization, continuous wearable data, and clinical history into a single risk model. No individual parameter drives the output. The interaction between findings does.

Among current approaches, AI-enhanced ECG analysis and MRI-based scar assessment appear most clinically promising for identifying high-risk patients before a first event. Limitations remain, including the need for external validation, concerns about algorithm bias, and limited clinical workflow integration.
The standard of care has not changed. But the direction is clear.

Learn more at hcp.medicalvisual.com!

Follow for clinically grounded cardiovascular education.

Secondary prevention of sudden cardiac death is built on a layered approach: addressing the substrate, suppressing the trigger, and protecting against recurrence.

ICDs remain the cornerstone for survivors of hemodynamically significant VT/VF without reversible cause.

Catheter ablation reduces arrhythmia burden and ICD therapies in scar-related VT, with growing use earlier in the disease course.

Coronary angiography and revascularization when indicated addresses ischemic triggers, though it does not replace device therapy in most survivors.

Pharmacotherapy with beta-blockers, amiodarone, mexiletine, or sotalol complements these interventions based on substrate and tolerability.

The goal is not a single definitive treatment, but a coordinated strategy matched to mechanism.

Learn more at hcp.medicalvisual.com!

Follow for clinically grounded cardiovascular education.